Education
About Us
Working with TipRanks
Follow Us
BONESUPPORT HOLDING AB (DE:2B4)
FRANKFURT:2B4
2B4 Stock Chart & Stats
€16.95
-€0.24(-0.69%)
At close: 4:00 PM EST
€16.95
-€0.24(-0.69%)
Day’s Range― - ―
52-Week Range€16.80 - €39.42
Previous CloseN/A
Volume165.00
Average Volume (3M)55.00
Market Cap
€1.12B
Enterprise Value€19.11B
Total Cash (Recent Filing)€379.02M
Total Debt (Recent Filing)€11.27M
Price to Earnings (P/E)82.3
Beta0.10
Next Earnings
Feb 12, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding65,859,190
10 Day Avg. Volume69
30 Day Avg. Volume55
Financial Highlights & Ratios
PEG Ratio-4.14
Price to Book (P/B)34.90
Price to Sales (P/S)28.25
P/FCF Ratio423.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BONESUPPORT HOLDING AB News
2B4 FAQ
What was BONESUPPORT HOLDING AB’s price range in the past 12 months?
BONESUPPORT HOLDING AB lowest stock price was €16.80 and its highest was €39.42 in the past 12 months.
What is BONESUPPORT HOLDING AB’s market cap?
BONESUPPORT HOLDING AB’s market cap is €1.12B.
When is BONESUPPORT HOLDING AB’s upcoming earnings report date?
BONESUPPORT HOLDING AB’s upcoming earnings report date is Feb 12, 2026 which is in 49 days.
How were BONESUPPORT HOLDING AB’s earnings last quarter?
BONESUPPORT HOLDING AB released its earnings results on Oct 23, 2025. The company reported €0.048 earnings per share for the quarter, missing the consensus estimate of €0.074 by -€0.026.
Is BONESUPPORT HOLDING AB overvalued?
According to Wall Street analysts BONESUPPORT HOLDING AB’s price is currently Overvalued.
Does BONESUPPORT HOLDING AB pay dividends?
BONESUPPORT HOLDING AB does not currently pay dividends.
What is BONESUPPORT HOLDING AB’s EPS estimate?
BONESUPPORT HOLDING AB’s EPS estimate is 0.08.
How many shares outstanding does BONESUPPORT HOLDING AB have?
BONESUPPORT HOLDING AB has 65,859,190 shares outstanding.
What happened to BONESUPPORT HOLDING AB’s price movement after its last earnings report?
BONESUPPORT HOLDING AB reported an EPS of €0.048 in its last earnings report, missing expectations of €0.074. Following the earnings report the stock price went down -4.514%.
Which hedge fund is a major shareholder of BONESUPPORT HOLDING AB?
Currently, no hedge funds are holding shares in DE:2B4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BONESUPPORT HOLDING AB
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.
2B4 Company Deck
2B4 Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong sales growth and successful product performance, particularly for CERAMENT G in the U.S., along with robust cash flow and strategic advancements such as the CeraHip study publication. However, these positive outcomes were tempered by significant currency impacts, challenges in key markets like Germany and the UK, technical disruptions during the call, and certain product sales declines.View all DE:2B4 earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---